Compare ADMA Biologics Inc (ADMA) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Booking Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.85 (market cap $2.22B), while Booking Holdings Inc trades at $210.04 (market cap $159.95B). The key difference: Booking Holdings Inc is far larger — about 72× ADMA Biologics Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BKNG | |
|---|---|---|
Market Cap | $2.22B | $159.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $228.83 |
52-Week Low | $7.60 | $154.13 |
Enterprise Value | $2.29B | $163.43B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Booking Holdings (BKNG) trades at $209.92, down 1.39% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates with $2.54 versus $2.43 expected, and maintains robust profitability with a 25.53% net income margin. Revenue growth continues, reaching $26.92B in 2025, supported by resilient travel demand.
The outlook remains positive with a consensus price target of $239.31, implying 14% upside, though risks include geopolitical volatility and rising debt levels. Analyst sentiment is strongly bullish with 64% buy ratings, while institutional interest is growing, as seen in recent filings. Earnings momentum and free cash flow generation support the investment case, but investors should monitor debt-to-asset trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
